Press Releases 2017

PROMETIC’S PBI-4050 RECEIVES PROMISING INNOVATIVE MEDICINE (PIM) DESIGNATION FROM THE UK MHRA IN THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS

PIVOTAL DATA FOR PROMETIC’S INTRAVENOUS PLASMINOGEN REPLACEMENT THERAPY TO BE PRESENTED AT AMERICAN SOCIETY FOR HEMATOLOGY

PROMETIC ANNOUNCES THE CLOSING OF ITS USD $80 MILLION (CAD $100 MILLION) LINE OF CREDIT WITH STRUCTURED ALPHA LP, AN AFFILIATE OF THOMVEST ASSET MANAGEMENT INC.

PROMETIC REPORTS POSITIVE INTERIM CLINICAL DATA FROM ONGOING INTRAVENOUS IMMUNOGLOBULIN (IVIG) PIVOTAL PHASE 3 TRIAL

PROMETIC REPORTS 2017 THIRD QUARTER HIGHLIGHTS AND FINANCIAL RESULTS

PROMETIC TO REPORT ITS THIRD QUARTER 2017 FINANCIAL RESULTS AND TO HOLD CONFERENCE CALL / WEBCAST

PROMETIC RECEIVES CLEARANCE FROM THE SWEDISH MEDICAL PRODUCTS AGENCY TO INITIATE PLASMINOGEN CLINICAL TRIAL IN CHRONIC TYMPANIC MEMBRANE PERFORATION

PROMETIC RECEIVES CLEARANCE FROM THE SWEDISH MEDICAL PRODUCTS AGENCY TO INITIATE PLASMINOGEN DIABETIC FOOT ULCER PHASE 2 CLINICAL TRIAL

PROMETIC RECEIVES FAST TRACK DESIGNATION FOR PBI-4050 IN DEVELOPMENT FOR IDIOPATHIC PULMONARY FIBROSIS (IPF)

PROMETIC ENTERS INTO BINDING LETTER OF INTENT TO SECURE USD $80 MILLION (CAD $100 MILLION) LINE OF CREDIT FROM STRUCTURED ALPHA LP, AN AFFILIATE OF THOMVEST ASSET MANAGEMENT INC.

X